Durham, North Carolina
Colorectal cancer clinical trials in Durham, NC
38 colorectal cancer studies are recruiting participants at sites in Durham as of November 16, 2026, according to ClinicalTrials.gov. Colorectal Cancer Clinical Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Durham at a glance
- 38 studies are recruiting at a site in Durham.
- By phase: Phase 1 (12), Phase 1/2 (9), Phase 2 (3), Phase 2/3 (1), Phase 3 (5), No phase (6), Observational (2). Studies of devices and behavioral approaches have no phase.
- By sponsor: industry (29), university, hospital or other (8), government (1).
- Most recent update to one of these records: November 16, 2026.
Studies recruiting in Durham
Basic details from each study's public record (the 30 most recently updated of 38). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- ECOG-ACRIN Cancer Research Group
- Study site
- Duke University Medical Center
- Registry record
- NCT05863195 · updated
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Astellas Pharma Global Development, Inc.
- Study site
- Duke Cancer Center Durham
- Registry record
- NCT07488676 · updated
The Vanguard Study: Testing a New Way to Screen for Cancer
- No phase
- Ages 45 to 75
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Durham VA Medical Center
- Registry record
- NCT06995898 · updated
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
- No phase
- Ages 45 to 70
- All sexes
- Sponsor
- NRG Oncology
- Study site
- Durham VA Medical Center
- Registry record
- NCT05080673 · updated
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- NRG Oncology
- Study site
- Duke University Medical Center
- Registry record
- NCT05174169 · updated
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Observational
- Ages 40 to 75
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- Durham VA Medical Center
- Registry record
- NCT05334069 · updated
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- Duke University Medical Center
- Registry record
- NCT07213791 · updated
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Sairopa B.V.
- Study site
- Duke Health - Duke University Hospital
- Registry record
- NCT05856981 · updated
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Alterome Therapeutics, Inc.
- Registry record
- NCT06835569 · updated
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- GlaxoSmithKline
- Study site
- GSK Investigational Site
- Registry record
- NCT06885034 · updated
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- AbbVie
- Study site
- Duke University Medical Center /ID# 279322
- Registry record
- NCT07525206 · updated
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Institut de Recherches Internationales Servier
- Study site
- Duke University School of Medicine
- Registry record
- NCT05786924 · updated
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- AbbVie
- Study site
- Duke University Medical Center /ID# 279457
- Registry record
- NCT07023289 · updated
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Pfizer
- Study sites
- Duke Cancer Center · Duke Cancer Center - Investigational Chemotherapy Service · Duke University Hospital - Vascular Interventional Radiology
- Registry record
- NCT07222800 · updated
FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Parabilis Medicines, Inc.
- Study site
- Duke University
- Registry record
- NCT05919264 · updated
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Phase 1/2
- Ages 12 and older
- All sexes
- Sponsor
- PMV Pharmaceuticals, Inc
- Study site
- Duke University
- Registry record
- NCT04585750 · updated
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Exelixis
- Study site
- Exelixis Clinical Site #12
- Registry record
- NCT05176483 · updated
A Study of PHN-012 in Patients With Advanced Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Pheon Therapeutics
- Study site
- PHN-012-001 Site
- Registry record
- NCT07127874 · updated
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Phanes Therapeutics
- Study site
- Duke Cancer Center
- Registry record
- NCT05482893 · updated
DESTINY-PANTUMOUR04
- Observational
- Ages 18 to 130
- All sexes
- Sponsor
- AstraZeneca
- Registry record
- NCT07124000 · updated
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- Revolution Medicines, Inc.
- Study site
- Duke University Medical Center
- Registry record
- NCT06445062 · updated
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- EvolveImmune United, Inc
- Study site
- Duke University Medical Center - Duke Cancer Center
- Registry record
- NCT07217171 · updated
Safety of HRX215 in Patients After Minor and Major Liver Resection
- Phase 1/2
- Ages 18 to 75
- All sexes
- Sponsor
- HepaRegeniX GmbH
- Study site
- Duke Cancer Institute
- Registry record
- NCT06638502 · updated
A Phase 1/1b Study of IAM1363 in HER2 Cancers
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Iambic Therapeutics, Inc
- Study site
- Duke Cancer Institute
- Registry record
- NCT06253871 · updated
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Amgen
- Study site
- Duke Cancer Center
- Registry record
- NCT06252649 · updated
Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections
- No phase
- Ages 18 and older
- All sexes
- Sponsor
- Medtronic - MITG
- Study site
- Duke University
- Registry record
- NCT07351071 · updated
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Kahr Bio Australia Pty Ltd
- Study site
- Duke University Medical Center - Duke Cancer Center
- Registry record
- NCT07235293 · updated
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Xencor, Inc.
- Study site
- Xencor Investigative Site
- Registry record
- NCT05433142 · updated
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Amgen
- Study site
- Duke Cancer Center
- Registry record
- NCT07094113 · updated
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Endevica Bio
- Study site
- Duke University Medical Center
- Registry record
- NCT06937177 · updated
Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Durham, NC on ClinicalTrials.gov.
Ask about studies near Durham
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections